1. Home
  2. SORA vs RNTX Comparison

SORA vs RNTX Comparison

Compare SORA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Top Win International Limited Ordinary Shares

SORA

Top Win International Limited Ordinary Shares

N/A

Current Price

$2.31

Market Cap

57.2M

Sector

Industrials

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.78

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SORA
RNTX
Founded
2001
2001
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.2M
65.3M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
SORA
RNTX
Price
$2.31
$0.78
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
13.4K
★ 337.1K
Earning Date
04-30-2027
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.25
$0.69
52 Week High
$5.98
$2.18

Technical Indicators

Market Signals
Indicator
SORA
RNTX
Relative Strength Index (RSI) 56.06 49.78
Support Level $2.07 $0.71
Resistance Level $2.54 $0.87
Average True Range (ATR) 0.15 0.06
MACD 0.01 0.00
Stochastic Oscillator 94.00 41.19

Price Performance

Historical Comparison
SORA
RNTX

About SORA Top Win International Limited Ordinary Shares

AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: